Optimal use of G-CSF administration after hematopoietic SCT
| Autor: | Meghana V. Trivedi, S Martinez, Sue Corringham, Edward D. Ball, Katherine Medley |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
medicine.medical_specialty Transplantation Conditioning Platelet Engraftment medicine.medical_treatment Graft vs Host Disease Hematopoietic stem cell transplantation Filgrastim Neutropenia Transplantation Autologous immune system diseases Internal medicine Granulocyte Colony-Stimulating Factor medicine Autologous transplantation Humans Transplantation Homologous Transplantation business.industry Hematopoietic Stem Cell Transplantation Hematology medicine.disease Surgery Granulocyte colony-stimulating factor surgical procedures operative Graft-versus-host disease Treatment Outcome business medicine.drug |
| Zdroj: | Bone marrow transplantation. 43(12) |
| ISSN: | 1476-5365 |
| Popis: | After hematopoietic SCT (HSCT), G-CSF is commonly used to enhance stem cell engraftment to minimize the morbidity and mortality associated with prolonged neutropenia. However, there is no consensus on the optimal use of G-CSF after high-dose chemotherapy followed by HSCT. This review was performed to evaluate the evidence regarding the use of G-CSF after autologous and allogeneic HSCT. Studies investigating the use of G-CSF in comparison to control (observation or placebo), early vs delayed initiation of G-CSF, and other approaches driven by patient-specific parameters to identify optimal use of G-CSF have been reviewed. Various outcomes such as neutrophil and platelet engraftment, post-transplant length of hospital stay, post-transplant complications such as infection and GVHD, and survival have been assessed. Finally, we provide the level of evidence for each of the outcomes analyzed while evaluating strategies for using G-CSF in patients undergoing autologous or allogeneic HSCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|